23andMe Investor Day Presentation Deck

Leveraging our database: I/O signature implicates CD200R1 pathway CD200R1 pathway identified as a critical immune checkpoint with our I/O genetic signature I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes CD200R1 Receptor Immune II Cancer Cancer CD200 Ligand Immune Immune Cancer DOK2 Protein -10 -5 0 5 10 Signed log(p) Implicates 3 components of the CD200R1 signaling pathway CD200:CD200R1 Signaling Tumor cell Reduced Anti-Tumor Immune Response CD200 Dok2 CD200R1 RasGAP ERK T-cell Ras We are applying similar approaches to many diseases that are well- represented in our database Copyright © 2022 23andMe, Inc. 23andMe® 21

View entire presentation